Supplemental Figure 13. from Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young
Year: 2026
Type: supplementary-materials
Abstract: Tumor growth (mean tumor volumes ± SEM), Kaplan–Meier curves (event defined as tumor exceeding 400 mm3 volume) and maximum loss in tumor volume were plotted for FP-RMS zcc27 (A-C), FP-RMS zcc31 (D-F), FP-RMS zcc81(G-I), FP-RMS zcc490 (J-L) and HGU zcc275 (M-O) PDX models treated with FGF401 100 mg/kg (twice daily oral gavage for 26 days, zcc27 and zcc31 only), lenvatinib 3mg/kg (daily oral gavage for 26 days, all models), ifosfamide 90 mg/kg and etoposide 6 mg/kg (once daily intraperitoneal injection on days 1-5 and 22-26, all models) or lenvatinib 3 mg/kg (daily oral gavage for 26 days, all models) and ifosfamide 90 mg/kg and etoposide 6 mg/kg (once daily intraperitoneal injection on days 1-5 and 22-26, all models). *: P < 0.05, ***: P < 0.001, ****: P < 0.0001 when compared to vehicle control by Mantel-Cox test.
Authors: Ashleigh M. Fordham, Lauren M. Brown, Chelsea Mayoh, Alice Salib, Zara A. Barger, Marie Wong, Terry C.C. Lim Kam Sian, Changyuan Hu, Jinhan Xie, Kate Gunther, Peter Trebilcock, Rachael L. Terry, Paulette Barahona, Pamela Ajuyah, Alexandra Sherstyuk, Anica Avila, Roxanne Cadiz, Callum M. Perkins, Andrew J. Gifford, Jie Mao, M. Emmy M. Dolman, Andrea Zhao, Luke P. O’Regan, Daniel Gorgels, Loretta M.S. Lau, David S. Ziegler, Michelle Haber, Vanessa Tyrrell, Richard B. Lock, Mark J. Cowley, Wayne Nicholls, Roger J. Daly, Paul G. Ekert, Emmy D.G. Fleuren
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7167063932